Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-26T12:11:46.128Z Has data issue: false hasContentIssue false
  • English
  • Français

Schizophrenia, antipsychotic drugs and cardiovascular risk: Descriptive study in primary care

Published online by Cambridge University Press:  15 April 2020

M. Castillo-Sánchez ,
M. Fàbregas-Escurriola ,
D. Bergè-Baquero ,
Q. Foguet-Boreu ,
M.I. Fernández-San Martín  and
A. Goday-Arno
M. Castillo-Sánchez*
Affiliation:
Institut Universitari d’Investigaciò en Atenciò Primaria (IDIAP) Jordi Gol, Barcelona, Spain Departamento de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Médico de familia, EAP Besòs, Barcelona, Spain
M. Fàbregas-Escurriola
Affiliation:
Institut Universitari d’Investigaciò en Atenciò Primaria (IDIAP) Jordi Gol, Barcelona, Spain Médico de familia EAP La Marina, Barcelona, Spain
D. Bergè-Baquero
Affiliation:
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Barcelona, Spain Unitat de Recerca en Neurcociència Cognitiva, Universitat Autònoma de Barcelona, Barcelona, Spain
Q. Foguet-Boreu
Affiliation:
Institut Universitari d’Investigaciò en Atenciò Primaria (IDIAP) Jordi Gol, Barcelona, Spain Hospital de Campdevànol, Girona, Spain Departamento de Ciencias Médicas, Facultad de Medicina, Universitat de Girona, Girona, Spain
M.I. Fernández-San Martín
Affiliation:
Institut Universitari d’Investigaciò en Atenciò Primaria (IDIAP) Jordi Gol, Barcelona, Spain Técnica de Salud ICS, Unitat Docent AFiC, Barcelona, Spain
A. Goday-Arno
Affiliation:
Departamento de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain Servicio de Endocrinología y Nutrición, Hospital del Mar, Barcelona, Spain CIBER Obn, Centro de Investigaciones Biomedicas en obesidad y nutrición. Parc de Salut Mar, Barcelona, Spain
*
*Corresponding author. CS Orihuela I, C. Madre Elisea 2b, cp 03300, Orihuela (Alicante), Spain. Tel.: +34966904053. E-mail address:doctor.miguel.castillo@gmail.com (M. Castillo-Sánchez).
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Schizophrenia and psychosisAntipsychoticsAddiction (consumption/abuse/dependence)Quality of careMiscellaneous
Type
Original article
Information
European Psychiatry , Volume 30 , Issue 4 , June 2015 , pp. 535 - 541
Copyright
Copyright © Elsevier Masson SAS 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ballesteros, A, Jiang, P, Summerfelt, A, Du, X, Chiappelli, J, O’Donnell, Pet al.No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia. Schizophr Res 2013;146(1–3):184–189.CrossRefGoogle Scholar
Bernardo, M, Cañas, F, Banegas, JR, Casademont, J, Riesgo, Y, Varela, CPrevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry 2009;24(7):431–441.CrossRefGoogle Scholar
Bobes, J, Arango, C, Aranda, P, Carmena, R, Garcia-Garcia, M, Rejas, JCardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007;90(1–3):162–173.CrossRefGoogle ScholarPubMed
Bolíbar, B, Fina Avilés, F, Morros, R, Garcia-Gil Mdel, M, Hermosilla, E, Ramos, Ret al.[SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research]. Med Clin (Barc) 2012;138(14):617–621. [Spanish].CrossRefGoogle Scholar
Brown, S, Birtwistle, J, Roe, L, Thompson, CThe unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697–701.CrossRefGoogle ScholarPubMed
Bushe, CJ, Taylor, M, Haukka, JMortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol 2010;24(4 Suppl.):17–25.CrossRefGoogle ScholarPubMed
Castillo Sánchez, M, Fàbregas Escurriola, M, Bergè Baquero, D, Goday Arno, A, Vallès Callol, JA[Psychosis, cardiovascular risk and associated mortality: are we on the right track?]. Clin Investig Arterioscler 2014;26(1):23–32. [Review. Spanish].Google Scholar
Conroy, RM, Pyöräla, K, Fitzgerald, AP, Sans, S, Menotti, A, De Backer, Get al.Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003.CrossRefGoogle ScholarPubMed
Correll, CUBalancing efficacy and safety in treatment with antipsychotics. CNS Spectr 2007;12(Suppl. 17):12–20.CrossRefGoogle ScholarPubMed
De Hert, M, Schreurs, V, Sweers, K, Van Eyck, D, Hanssens, L, Sinko, Set al.Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008;101(1–3):295–303.CrossRefGoogle ScholarPubMed
De Hert, M, Dekker, JM, Wood, D, Kahl, KG, Holt, RI, Möller, HJCardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24(6):412–424.CrossRefGoogle Scholar
Departament de Salut - Generalitat de Catalunya Llibre blanc: consens sobre les activitats preventives a l’edat adulta dins l’atenció primària, 2nd ed, Barcelona: Direcció General de Salut Pública; 2005.Google Scholar
Dipasquale, S, Pariante, CM, Dazzan, P, Aguglia, E, McGuire, P, Mondelli, VThe dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res 2013;47(2):197–207.CrossRefGoogle ScholarPubMed
Fagiolini, A, Goracci, AThe effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry 2009;70(3 Suppl.):22–29.CrossRefGoogle ScholarPubMed
Fan, Z, Wu, Y, Shen, J, Ji, T, Zhan, RSchizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res 2013;47(11):1549–1556.CrossRefGoogle ScholarPubMed
Fernandez-Egea, E, Bernardo, M, Donner, T, Conget, I, Parellada, E, Justicia, Aet al.Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 2009;194(5):434–438.CrossRefGoogle ScholarPubMed
Fleischhacker, WW, Siu, CO, Bodén, R, Pappadopulos, E, Karayal, ON, Kahn, RSet al.Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol 2013;16(5):987–995.CrossRefGoogle ScholarPubMed
Foley, DL, Morley, KISystematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011;68:609–616.CrossRefGoogle Scholar
García-Gil Mdel, M, Hermosilla, E, Prieto-Alhambra, D, Fina, F, Rosell, M, Ramos, Ret al.Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care 2011;19(3):135–145.Google Scholar
Goff, DC, Sullivan, LM, McEvoy, JP, Meyer, JM, Nasrallah, HA, Daumit, GLet al.A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005;80(1):45–53.CrossRefGoogle ScholarPubMed
Green, AI, Brown, ESComorbid schizophrenia and substance abuse. J Clin Psychiatry 2006;67(9):e08.CrossRefGoogle ScholarPubMed
Hansen, T, Ingason, A, Djurovic, S, Melle, I, Fenger, M, Gustafsson, Oet al.At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry 2011;70(1):59–63.CrossRefGoogle ScholarPubMed
Kelly, DL, McMahon, RP, Liu, F, Love, RC, Wehring, HJ, Shim, JCet al.Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry 2010;71(3):304–311.CrossRefGoogle ScholarPubMed
Kessing, LV, Thomsen, AF, Mogensen, UB, Andersen, PKTreatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010;197(4):266–271.CrossRefGoogle ScholarPubMed
Kilbourne, AM, Morden, NE, Austin, K, Ilgen, M, McCarthy, JF, Dalack, Get al.Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry 2009;31(6):555–563.CrossRefGoogle Scholar
Kirkpatrick, B, Miller, BJ, Garcia-Rizo, C, Fernandez-Egea, E, Bernardo, MIs abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosisconfounded by poor health habits? Schizophr Bull 2012;38(2):280–284.CrossRefGoogle ScholarPubMed
Laursen, TM, Munk-Olsen, T, Agerbo, E, Gasse, C, Mortensen, PBSomatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 2009;66(7):713–720.CrossRefGoogle ScholarPubMed
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31–41.CrossRefGoogle ScholarPubMed
Manu, P, Correll, CU, Wampers, M, van Winkel, R, Yu, W, Shiffeldrim, Det al.Dysmetabolic features of the overweight patients receiving antipsychotic drugs: a comparison with normal weight and obese subjects. Eur Psychiatry 2014;29(3):179–182.CrossRefGoogle ScholarPubMed
Marrugat, J, Solanas, P, D’Agostino, R, Sullivan, L, Ordovas, J, Cordón, Fet al.[Coronary risk estimation in Spain using a calibrated Framingham function]. Rev Esp Cardiol 2003;56(3):253–261. [Spanish].CrossRefGoogle Scholar
Mitchell, AJ, Lord, ODo deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis. J Psychopharmacol 2010;24(4 Suppl.):69–80.CrossRefGoogle ScholarPubMed
Mitchell, AJ, Vancampfort, D, Sweers, K, van Winkel, R, Yu, W, De Hert, MPrevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull 2013;39(2):306–318.CrossRefGoogle ScholarPubMed
Nordentoft, M, Wahlbeck, K, Hällgren, J, Westman, J, Osby, U, Alinaghizadeh, Het al.Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One 2013;8(1):e55176.CrossRefGoogle ScholarPubMed
O’Donnell, CJ, Elosua, R[Cardiovascular risk factors. Insights from Framingham Heart Study]. Rev Esp Cardiol 2008;61(3):299–310. [Review. Spanish].CrossRefGoogle Scholar
Ryan, MC, Collins, P, Thakore, JHImpaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160(2):284–289.CrossRefGoogle ScholarPubMed
Smith, DJ, Langan, J, McLean, G, Guthrie, B, Mercer, SWSchizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open 2013;3(4).CrossRefGoogle ScholarPubMed
Spelman, LM, Walsh, PI, Sharifi, N, Collins, P, Thakore, JHImpaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 2007;24:481–485.CrossRefGoogle ScholarPubMed
Tiihonen, J, Lönnqvist, J, Wahlbeck, K, Klaukka, T, Niskanen, L, Tanskanen, Aet al.11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374(9690):620–627.CrossRefGoogle Scholar
Vancampfort, D, Wampers, M, Mitchell, AJ, Correll, CU, De Herdt, A, Probst, Met al.A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013;12(3):240–250.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.